Ultragenyx reported earnings of ($1.06) per share beat views
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported Q2 2018 earnings, coming in at ($1.06) per share, beating Wall Street’s estimates of ($2.08) per Share. Revenue for the quarter came in at $12.79 million missing the streets estimates of $5.63 million
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.